Compare Ecopetrol SA (EC) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Gilead Sciences, Inc. — how do they compare? Ecopetrol SA trades at $16.91 (market cap $33.11B), while Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 5.5× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (3.83%). Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Gilead Sciences, Inc. for 111 Days on average.
| EC | GILD | |
|---|---|---|
Market Cap | $33.11B | $182.40B |
Volume | 993,598 | 4,469,821 |
Sector | Energy | Health |
52-Week High | $18.26 | $155.80 |
52-Week Low | $8.61 | $116.74 |
Typical Hold Time | 84 Days | 111 Days |
Enterprise Value | $61.36B | $205.46B |
Dividend Yield | 3.83% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.94, up 1.86% with bearish technical signals despite recent management changes. The stock shows attractive valuation metrics with P/E of 7.97 and EV/EBITDA of 4, but faces declining revenue from $159.6B in 2022 to $119.7B in 2025. Recent earnings misses and a mixed analyst consensus (27% Buy, 55% Hold) reflect uncertainty amid ongoing corporate restructuring and government involvement.
Investment outlook remains cautious with near-term headwinds from management transitions and revenue pressures offset by undervalued fundamentals. Key risks include political interference and execution challenges during transformation, while potential upside exists if new leadership can stabilize operations and reverse earnings trajectory.
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
